Literature DB >> 19158362

Cross-talk between integrins and oncogenes modulates chemosensitivity.

Jordi Carreras Puigvert1, Stephan Huveneers, Lisa Fredriksson, Marieke op het Veld, Bob van de Water, Erik H J Danen.   

Abstract

Chemotherapy often relies on cancer cell death resulting from DNA damage. The p53 tumor suppressor pathway that is an important player in DNA damage response is frequently inactivated in cancer. Genotoxicants also activate DNA damage-independent stress pathways and activity of oncogenic signaling and adhesive interactions with the cancer microenvironment can have a strong impact on chemosensitivity. Here, we have investigated how two different oncogenes modulate the response to genotoxicants in the context of two classes of integrin adhesion receptors. Epithelial cells expressing either beta1 or beta3 integrins, in which p53 activity is suppressed, undergo G(2) arrest but show little apoptosis after treatment with cisplatin or other genotoxicants. The apoptotic response is strongly enhanced by the c-Src[Y530F] oncogene in cells expressing beta1 integrins, whereas such sensitization is reduced when these cells are engineered to express beta3 integrins instead. The H-Ras[G12V] oncogene fails to sensitize, regardless of the integrin expression profile. The enhanced sensitivity induced by c-Src[Y530F] in the context of beta1 integrins does not rely on p53-mediated DNA damage signaling but instead involves increased endoplasmic reticulum stress and caspase-3 activation. Our data implicate that the expression profiles of oncogenes and integrins strongly affect the response to chemotherapeutics and may thus determine the efficacy of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158362     DOI: 10.1124/mol.108.051649

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Integrin αβ1, αvβ, α6β effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance.

Authors:  Hope A Sansing; Ali Sarkeshik; John R Yates; Vyomesh Patel; J Silvio Gutkind; Kenneth M Yamada; Allison L Berrier
Journal:  Biochem Biophys Res Commun       Date:  2011-02-01       Impact factor: 3.575

2.  ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.

Authors:  David A Tumbarello; Jillian Temple; James D Brenton
Journal:  Mol Cancer       Date:  2012-05-28       Impact factor: 27.401

3.  Proteomic dissection of cell type-specific H2AX-interacting protein complex associated with hepatocellular carcinoma.

Authors:  Xiaoli Yang; Peng Zou; Jun Yao; Dong Yun; Huimin Bao; Ruyun Du; Jing Long; Xian Chen
Journal:  J Proteome Res       Date:  2010-03-05       Impact factor: 4.466

4.  Intracellular targets of RGDS peptide in melanoma cells.

Authors:  Maria Simona Aguzzi; Paola Fortugno; Claudia Giampietri; Gianluca Ragone; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

Review 5.  Cancer Systems Biology: a peek into the future of patient care?

Authors:  Henrica M J Werner; Gordon B Mills; Prahlad T Ram
Journal:  Nat Rev Clin Oncol       Date:  2014-02-04       Impact factor: 66.675

6.  Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB.

Authors:  Karen E Eberle; Hope A Sansing; Peter Szaniszlo; Vicente A Resto; Allison L Berrier
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

7.  Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair.

Authors:  Oliver Zschenker; Thomas Streichert; Stephanie Hehlgans; Nils Cordes
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.